Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rIX-FP in children with hemophilia B
NCT01662531Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Jan 2013
- Primary completion
- Oct 2014
- Modality
- Fc-Fusion Proteins
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of albutrepenonacog alfa in hemophilia B (HB), sponsored by CSL Limited. Primary endpoints: Incremental Recovery Following a Single Intravenous Dose, Half-life (t1/2) Following a Single Intravenous Dose and 3 more. Started Jan 2013; status: completed.
02
Drugs
albutrepenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT01662531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01662531.